市場調查報告書

全球偏頭痛藥物市場:2019-2026

Global Migraine Drugs Market - 2019-2026

出版商 DataM Intelligence 商品編碼 950567
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
全球偏頭痛藥物市場:2019-2026 Global Migraine Drugs Market - 2019-2026
出版日期: 2020年07月18日內容資訊: 英文
簡介

偏頭痛可能是神經系統疾病最常見的原因。近年來,偏頭痛病例的數量已大大增加。例如,根據2015年國家生物技術信息中心的數據,偏頭痛在某時影響著20%以上的人。根據流行病學調查,近4.5%的西歐人口每月至少有15天頭痛。研究還表明,偏頭痛在美國影響了超過3100萬人,是美國第三大常見疾病,甚至可能是導致殘疾的第二大原因。因此,偏頭痛治療的激增有望成為市場增長的主要動力。此外,增加使用有害產品和增加慢性病患病率是偏頭痛藥物需求增加的主要原因。

與偏頭痛藥物相關的副作用可能會限制市場的增長。但是,可支配市場的增長和偏頭痛患者的增加正在推動新興市場的需求,這為市場參與者提供了廣泛的增長機會。

本報告對全球偏頭痛藥物市場進行了調查和分析,並提供了有關行業分析,細分市場分析,競爭格局和主要公司的系統信息。

內容

第1章市場研究方法和範圍

  • 調查方法
  • 調查目的和調查範圍

第2章市場定義和概述

第3章執行摘要

  • 按類型細分的市場
  • 按藥物途徑細分的市場
  • 按分銷渠道細分的市場
  • 區域市場細分

第4章市場動態

  • 影響市場的因素
    • 生長因子
    • 抑制因子
    • 影響分析
  • 市場機會
  • 趨勢

第5章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 法規分析
  • 價格分析

第6章全球偏頭痛藥物市場(按類型)

  • 簡介
    • 按類型劃分的市場規模分析和同比增長分析(%)
    • 按類型劃分的市場吸引力指數
  • 漸進性預防藥物
    • 簡介
    • 2017-2026年市場規模分析(百萬美元)和2018-2026年同比增長分析(%)
  • 預防

第7章全球偏頭痛藥物市場(通過藥物治療途徑)

  • 簡介
    • 按用藥途徑進行的市場規模分析和同比增長分析(%)
    • 用藥途徑的市場吸引力指數
  • 經口
  • 注射
  • 其他

第8章全球偏頭痛藥物市場-通過分銷渠道

  • 簡介
    • 按分銷渠道進行的市場規模分析和按年增長分析(%)
    • 按分銷渠道劃分的市場吸引力指數
  • 醫院藥房
    • 簡介
    • 2016-2025年市場規模分析(百萬美元)和2018-2026年同比增長分析(%)
  • 零售藥房
  • 線上藥房

第9章按地區劃分的偏頭痛治療劑的全球市場

  • 簡介
    • 市場規模分析,按年增長率分析(%),按地區
    • 按地區劃分的市場吸引力指數
  • 北美
    • 簡介
    • 特定地區的主要動態
    • 按類型劃分的市場規模分析和同比增長分析(%)
    • 按用藥途徑進行的市場規模分析和同比增長分析(%)
    • 按分銷渠道進行的市場規模分析和按年增長分析(%)
    • 按國家/地區劃分的市場規模分析和同比增長分析(%)
  • 歐洲
    • 簡介
    • 特定地區的主要動態
    • 按類型劃分的市場規模分析和同比增長分析(%)
    • 按用藥途徑進行的市場規模分析和同比增長分析(%)
    • 按分銷渠道進行的市場規模分析和按年增長分析(%)
    • 按國家/地區劃分的市場規模分析和同比增長分析(%)
  • 南美洲
    • 簡介
    • 特定地區的主要動態
    • 按類型劃分的市場規模分析和同比增長分析(%)
    • 按用藥途徑進行的市場規模分析和同比增長分析(%)
    • 按分銷渠道進行的市場規模分析和按年增長分析(%)
    • 按國家/地區劃分的市場規模分析和同比增長分析(%)
  • 亞太地區
    • 簡介
    • 特定地區的主要動態
    • 按類型劃分的市場規模分析和同比增長分析(%)
    • 按用藥途徑進行的市場規模分析和同比增長分析(%)
    • 按分銷渠道進行的市場規模分析和按年增長分析(%)
    • 按國家/地區劃分的市場規模分析和同比增長分析(%)
  • 中東和非洲
    • 簡介
    • 特定地區的主要動態
    • 按類型劃分的市場規模分析和同比增長分析(%)
    • 按用藥途徑進行的市場規模分析和同比增長分析(%)
    • 按分銷渠道進行的市場規模分析和按年增長分析(%)

第10章競爭情況

  • 競爭情景
  • 市場定位/佔有率分析
  • 併購分析

第11章公司簡介

  • Abbott Laboratories
    • 公司概述
    • 投資組合和說明
    • 主要亮點
    • 財務概覽
  • AbbVie Inc
  • Allergan Plc..
  • AstraZeneca PLC.
  • Eisai Co., Ltd.
  • Endo International Plc.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • 其他

第12章全球偏頭痛藥物市場-重要注意事項

第13章全球偏頭痛藥物市場:DataM

  • 附錄
  • 關於我們和服務
  • 聯繫我們
目錄

Market Overview

Migraine is a condition of the neurology which can cause multiple symptoms. It is marked often by severe and debilitating headaches. Symptoms can include nausea, vomiting, difficulty speaking, numbness or tingling, and others. Migraines occur inside families and influence all ages. Diagnosis of migraine headaches is assessed from clinical history and reported symptoms. Migraines may arise in infancy or may not appear until early adulthood. Females are more prone to experience migraines than men. Genetic background is one of the most common sign factors for migraines. Symptoms of migraines will start one to two days before the headache itself. This is classified as a stage of the prodrome. Migraine pain more often impacts the area of the forehead. It's normally on one side of the head, but on both sides, it may occur. The Migraine Drugs market valued USDXX million in 2018 and it is expected to grow at a CAGR of XX% to reach USD XX million by 2026.

Market Dynamics:

Migraine is perhaps the most common cause of disability in neurology. There has been a substantial increase in migraine cases in recent years. For instance, in 2015, As per the National Center for Biotechnology Information, migraine impacts more than 20 percent of people at some point in their lives in 2015; epidemiological studies have shown that almost 4.5 percent of Western Europe's population has a headache on at least 15 days a month. As per the study, migraine also affects upwards of 31 million people in the United States and is the third most common disease and perhaps even the second leading cause of disability worldwide. Thus, a surge in migraine medications is expected to be a key factor in market growth. In addition, the growing use of unhealthy products and the increasing prevalence of chronic disease are the main factors responsible for the rise of the demand for migraine drugs.

Side effects associated with migraine drugs may act as restrain for market growth. However, there is growing demand emerging market, due to rising disposal income and increasing numbers of migraine patients are expected to present a wide range of growth opportunities for market players.

Segment Analysis

Global migraine drugs are segmented into treatment type, route of administration, and distribution channel. Based on the treatment type, the market is segmented into prophylactic and abortive. On the basis of route of administration, the market is segmented into injectable, oral, and others. Based in distribution channel, the global migraine drugs market is diversified as hospital pharmacies, retail pharmacies, and others.

Currently, there are three novel drugs in late-stage pipeline that are set to change the treatment landscape. These drugs follow disease-modifying approaches and are associated with superior clinical efficacy and a favorable safety profile compared to currently marketed drugs.

Allergan's ubrogepant and Eli Lilly's Lasmiditan are expected to be first-in-class migraine drugs with novel mechanism of actions for patients unresponsive to triptans or those who are at risk of cardiovascular disorders.Several triptans under late-stage development consist of reformulation of generic triptans, with an aim to improve the efficacy of existing formulations. Zosano Pharma's M207 is being investigated in Phase III ADAM (NCT03282227) trial. The drug is a novel formulation of zolmitriptan delivered via Zosano's proprietary Adhesive Dermally-Applied Microarray (ADAM) technology.

Geographical Presentation

By region, the Migraine Drugs market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the Migraine Drugs market due to the high usage of the Migraine Drugs. Additionally, Migraine is the third most prevalent and the sixth most disabling illness in the world, affecting more than 37 million in the U.S. and over one billion people worldwide. United States dominated the market with more than 65% share in 2017 and is projected to maintain its position until 2025. Launch of CGRP based therapies, high prevalence, increasing adoption of novel therapeutics, and a large target population in the U.S. is some of the factors contributing to the dominance of the country

Competitive Analysis

Key players operating in the market are Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, and others. Leading multinational players dominate the market and hold substantial market share, thereby, presenting tough competition to new entrants. Key players focus on various strategic initiatives such as merger & acquisition, geographical expansion, new product launch and increasing R&D expenditure to stay competitive in the market. For instance, in 2019 Allergen Company announced that a New Drug Application for UBRELVY for the acute treatment of migraines with or without aura in adults. This drug was approved by the Food and Drug Administration (United States). This acquisition will affect the growth of the market in the future.

Until 2017, Allergan's Botox, a neurotoxin was in a strong competitive position in the preventive migraine market. As the only drug approved for prevention, Botox commanded premium pricing with more than 60.0% market share in 2017. However, Botox is expected to face competition from launch of Amgen/Novartis' Aimovig and other highly efficacious CGRP-based therapies, which target both chronic and episodic migraine, as opposed to Botox, which is only approved for the chronic variant of the condition.

Why Purchase the Report?

  • Visualize the composition of the Migraine Drugs market products in terms of data type, business function, component, deployment model, organization size, and industrial vertical highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the Migraine Drugs market by analyzing trends and co-development deals.
  • Excel datasheet with thousands of data points of global Migraine Drugs market-level4/5segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • *The global Migraine Drugs market report will provide access to approximately 63 Market data tables, 51 figures, and 178 pages

Target Audience

  • Drug Manufacturers
  • Drug Suppliers, Distributors
  • Government Regulatory Bodies
  • Market Research Organization
  • Others

Table of Contents

1. Global Migraine Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Migraine Drugs Market-Market Definition and Overview

3. Global Migraine Drugs Market-Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Route of Admistration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Migraine Drugs Market-Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Impact Analysis
  • 4.2. Opportunity
  • 4.3. Trends

5. Global Migraine Drugs Market-Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis

6. Global Migraine Drugs Market - By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Abortive Medicine *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis,USDMn,2017-2026 and Y-o-Y Growth Analysis(%),2018-2026
  • 6.3. Preventive Medicine

7. Global Migraine Drugs Market - By Route of Admistration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Route of Admistration
    • 7.1.2. Market Attractiveness Index, By Route of Admistration
  • 7.2. Oral*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market SizeAnalysis,US$Mn,2016-2025andY-o-YGrowthAnalysis(%),2018-2026
  • 7.3. Injectable
  • 7.4. Others

8. Global Migraine Drugs Market - By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital-Based Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. Global Migraine Drugs Market-By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, andY-o-Y Growth Analysis(%),By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis(%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Route of Admistration
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis(%),By Distribution Channel

10. Global Migraine Drugs Market Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Migraine Drugs Market Company Profiles

  • 11.1. Abbott Laboratories *
    • 11.1.1. Company Overview
    • 11.1.2. Form Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. AbbVie Inc
  • 11.3. Allergan Plc..
  • 11.4. AstraZeneca PLC.
  • 11.5. Eisai Co., Ltd.
  • 11.6. Endo International Plc.
  • 11.7. GlaxoSmithKline Plc.
  • 11.8. Merck & Co., Inc.
  • 11.9. Pfizer Inc.
  • 11.10. Johnson & Johnson
  • List is not exhaustive

12. Global Migraine Drugs Market-Premium Insights

13. Global Migraine Drugs Market-DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us